Understanding Potency in Peptide Research
The concentration-response relationship sits at the heart of pharmacological characterisation. When a peptide compound interacts with a receptor or enzyme, the magnitude of the observed effect changes as a function of concentration, and the mathematical description of that relationship encodes a remarkable amount of information about binding affinity, mechanism, and assay conditions. Yet the single number most commonly extracted from this relationship — the EC50 — is also one of the most frequently misinterpreted figures in the research literature.
EC50, the half-maximal effective concentration, represents the concentration of a compound required to produce 50% of its maximum observed effect in a given assay system [1]. That qualifier — in a given assay system — is critical and often omitted when values are cited. EC50 is not an intrinsic molecular property in the way that molecular weight is. It is a system-dependent parameter, shaped by receptor expression levels, cell type, buffer composition, temperature, assay format, and a range of other experimental variables. Understanding this distinction is the first step toward reading potency data with appropriate rigour.
EC50: Definition, Calculation, and Common Misconceptions
The EC50 is derived by fitting concentration-response data to a sigmoidal curve, most commonly the four-parameter logistic (4PL) model, which takes the general form of the Hill equation [1]. The four parameters describe the minimum response (bottom plateau), maximum response (top plateau), the midpoint of the curve (EC50), and the steepness of the transition (the Hill coefficient). Each of these parameters carries interpretive weight, and errors in estimating any one of them propagate into errors in the others.
A common misconception is that a lower EC50 invariably indicates a more potent or more efficacious compound. Potency and efficacy are distinct concepts. Potency refers to the concentration required to achieve a given effect, while efficacy describes the maximum effect achievable regardless of dose [1]. A compound with an EC50 of 1 nM that produces only 30% of the maximum receptor activation achievable by a reference agonist is less efficacious than a compound with an EC50 of 100 nM that produces full activation. Comparing EC50 values without accounting for the maximum response — the Emax — produces an incomplete and potentially misleading picture of a compound's pharmacological profile.
A second misconception concerns the precision of EC50 estimates. Because EC50 is the midpoint of a sigmoidal curve, it is most reliably estimated when the curve is well-defined: that is, when experimental data points span concentrations both well below and well above the EC50, establishing clear lower and upper plateaus. When data are available only across a narrow concentration range, or when the curve lacks a clear upper plateau, the EC50 estimate becomes highly sensitive to the fitting algorithm and initial parameter assumptions. Such estimates should be treated with considerable caution [6].
Hill Coefficients: Sigmoidicity, Cooperativity, and Mechanistic Signals
The Hill coefficient (often denoted n or h) describes the steepness of the sigmoidal transition in a dose-response curve. For a simple, non-cooperative interaction between a ligand and a single binding site, the Hill coefficient is expected to be approximately 1.0, producing a curve that spans roughly two orders of magnitude in concentration between 10% and 90% of maximum effect [3].
Deviations from unity are mechanistically informative. A Hill coefficient substantially greater than 1 — sometimes described as steep or superunitary — suggests positive cooperativity, where binding of one ligand molecule facilitates subsequent binding events. This is classically observed in multi-subunit proteins such as haemoglobin, but can also arise from receptor oligomerisation, allosteric mechanisms, or signal amplification within the assay readout itself [3]. Conversely, a Hill coefficient below 1 produces a shallower curve and may indicate negative cooperativity, receptor heterogeneity within the assay population, or the simultaneous occupation of multiple receptor subtypes with differing affinities.
For peptide compounds specifically, non-unity Hill coefficients warrant careful scrutiny. A Hill coefficient of 1.8 observed in a cell-based calcium flux assay might reflect genuine positive cooperativity at the receptor level, or it might reflect the amplified, threshold-like nature of intracellular calcium signalling downstream of receptor activation. Distinguishing between these interpretations requires orthogonal assay approaches — for instance, comparing the Hill coefficient observed in a direct binding assay against that observed in a functional readout. When such comparisons are absent from a publication, the mechanistic interpretation of an unusual Hill coefficient remains speculative [3].
Values that are dramatically non-unity — Hill coefficients of 0.3 or 3.0, for example — should prompt consideration of whether the data are actually following a simple monophasic dose-response relationship at all. Biphasic responses, where two distinct populations of receptors or two distinct mechanisms contribute to the overall signal, can produce apparent Hill coefficients that deviate substantially from unity when incorrectly fitted with a single sigmoidal model [6].
Cell-Based Versus Biochemical Assays: Why Platform Matters
The same peptide compound evaluated in a biochemical binding assay and a cell-based functional assay will frequently yield different EC50 values, sometimes by an order of magnitude or more [2]. This is not a sign that one measurement is wrong. It reflects the fundamentally different questions each assay format is asking.
A biochemical assay — such as a competitive radioligand binding experiment or a fluorescence polarisation displacement assay — measures the direct interaction between the compound and an isolated receptor or protein preparation. The result is typically expressed as an IC50 (the concentration inhibiting 50% of a reference ligand's binding) or a Ki (the equilibrium inhibition constant), and reflects affinity under defined, controlled conditions. There is no cellular machinery, no signal transduction cascade, and no receptor trafficking.
A cell-based functional assay — such as a cAMP accumulation assay, a calcium mobilisation assay, or a reporter gene assay — measures the downstream consequence of receptor activation within a living cell. Here, signal amplification is substantial. A receptor that is occupied at only 1% of its total population may generate a measurable functional response if the downstream signalling cascade amplifies that initial signal many-fold. This amplification effect means that functional EC50 values are frequently lower than binding IC50 values for full agonists, a phenomenon described by receptor reserve or spare receptors [1].
For researchers comparing potency data across publications, this distinction is foundational. An EC50 of 5 nM in a cAMP assay and a Ki of 50 nM from a binding assay for the same compound are not contradictory — they are measuring different aspects of the same pharmacological interaction. Treating them as equivalent, or ranking compounds based on a mixture of binding and functional potency values, introduces systematic error into any comparative analysis [2].
Sources of Assay Variability and Their Effects on Reproducibility
Even within a single assay format, EC50 measurements are subject to considerable variability from sources that are not always reported in publications. Understanding these sources is essential for interpreting confidence intervals and for assessing whether differences between reported values are pharmacologically meaningful or simply reflective of experimental noise [5].
Biological Variables
Cell passage number exerts a well-documented influence on receptor expression levels and cellular physiology. A cell line at passage 10 may express a receptor at substantially different density than the same line at passage 40, and because functional EC50 values are sensitive to receptor reserve, this translates directly into shifts in apparent potency [2]. Temperature affects both binding kinetics and the activity of downstream signalling enzymes; assays conducted at room temperature versus 37°C can yield meaningfully different results. pH influences the ionisation state of both the peptide compound and the receptor binding site, with even small deviations from physiological pH altering binding affinity for charged or titratable residues [5].
Assay Design Variables
Buffer composition — ionic strength, the presence of divalent cations, the inclusion of serum proteins — affects peptide stability, aggregation propensity, and non-specific binding. Peptides with a tendency to aggregate at higher concentrations can produce artifactually shallow or biphasic curves, as the aggregated fraction may be pharmacologically inactive or may interact with the assay system in unintended ways. Receptor expression density, whether in a transfected overexpression system or an endogenous expression context, directly modulates the relationship between occupancy and response [5].
Incubation time and the order of reagent addition are less frequently discussed but equally consequential. For peptide agonists, extended pre-incubation periods can induce receptor internalisation or desensitisation, reducing the apparent maximum response and shifting the apparent EC50 [7]. This is particularly relevant in assay formats that require prolonged compound exposure before the readout is taken.
Assessing Curve Quality Before Interpreting Parameters
Before any EC50 value is accepted as meaningful, the underlying curve from which it was derived deserves scrutiny. A well-characterised dose-response curve should exhibit several properties: a clear lower plateau at sub-effective concentrations, a clear upper plateau at saturating concentrations, a smooth sigmoidal transition between them, and data points distributed across the full concentration range rather than clustered around the midpoint.
Incomplete curves — those lacking a defined upper plateau because the highest tested concentration was insufficient to achieve saturation — yield EC50 estimates that are extrapolated beyond the data rather than interpolated within it. Such extrapolations are highly sensitive to the assumed maximum response and should be flagged as provisional. Similarly, curves where the lower plateau is poorly defined because the lowest tested concentration already produces a measurable effect cannot reliably distinguish between a low-EC50 compound and a high-background assay [6].
Data fitting software will produce parameter estimates regardless of curve quality, and the numerical output of a fitting routine carries no inherent indication of whether the underlying data support the model. Researchers should examine the confidence intervals around the EC50 estimate — a 95% confidence interval spanning two orders of magnitude indicates a poorly constrained fit — and should inspect the residuals from the fit for systematic patterns that might indicate model misspecification.
Translating In Vitro Potency to In Vivo Efficacy
The gap between a nanomolar EC50 measured in a cell-based assay and the dose required to produce a meaningful biological effect in an animal study — let alone in a clinical context — is substantial and frequently underappreciated [4]. Multiple factors contribute to this translation gap.
Pharmacokinetic properties determine how much of an administered dose reaches the target tissue at concentrations relevant to the EC50. For peptide compounds, proteolytic degradation, renal clearance, and limited membrane permeability often result in rapid elimination and low bioavailability, meaning that systemic concentrations may never approach the EC50 measured in a protected, buffered assay environment. Protein binding in plasma reduces the free fraction of compound available for receptor interaction. Distribution into the target tissue may be incomplete, particularly for targets within the central nervous system where the blood-brain barrier imposes additional constraints [4].
Preclinical data from animal studies can begin to bridge this gap, but species differences in receptor pharmacology, metabolic enzyme activity, and tissue distribution introduce additional uncertainty. Early-stage research has explored the relationship between in vitro potency and in vivo dose requirements for various peptide classes, consistently finding that potency rankings established in cell-based assays do not reliably predict rank-ordering of in vivo efficacy [4]. A compound with a tenfold lower EC50 in vitro does not automatically require a tenfold lower dose in vivo.
Comparing Potency Across the Literature
The challenges described above compound when attempting to compare EC50 values reported by different laboratories for the same compound, or when comparing structurally related compounds evaluated in different studies. Standardisation of assay conditions across laboratories is limited, and reporting of methodological detail in publications is often insufficient to permit meaningful comparison [5].
Practical steps for critical literature evaluation include: identifying the assay format (biochemical versus functional, and the specific readout used); noting the cell line and passage range; checking whether the full concentration-response curve is shown or whether only the EC50 is reported; examining the confidence intervals or standard error of the EC50 estimate; and considering whether the Hill coefficient is reported and whether it is consistent with the proposed mechanism. When these details are absent, the reported EC50 should be treated as a rough indicator of potency order-of-magnitude rather than a precise, reproducible value.
Statistical Power and Replication in Potency Studies
Dose-response experiments are frequently conducted with limited replication — three to four independent experiments is common — and the statistical power to detect modest differences in EC50 between compounds is correspondingly limited [6]. A twofold difference in EC50, which might appear pharmacologically meaningful, falls well within the variability attributable to assay conditions alone and is unlikely to reach statistical significance in a modestly powered experiment.
Confidence intervals around EC50 estimates provide more information than p-values in this context, as they directly express the range of values consistent with the observed data given the model assumptions. When confidence intervals for two compounds overlap substantially, the difference in their point-estimate EC50 values should not be interpreted as a reliable ranking of potency. Researchers designing potency comparison studies benefit from power calculations conducted prior to data collection, using estimates of assay variability derived from historical data within their specific experimental system [6].
Conclusion
EC50 values are indispensable tools for characterising peptide compounds in research settings, but their utility depends entirely on the rigour with which they are measured, reported, and interpreted. A single number extracted from a dose-response curve carries within it the influence of the assay platform, the biological system, the experimental conditions, and the statistical methodology used to fit the data. Researchers who read potency claims with attention to these underlying factors — who ask not just what the EC50 is, but how it was measured and whether the curve supports the estimate — are equipped to extract genuine insight from the pharmacological literature rather than accumulating a collection of decontextualised numbers.